Guidant Corp. has accepted Boston Scientific’s acquisition offer of about $27 billion in cash and stock. Boston Scientific had been vying with Johnson and Johnson for a chance to acquire Guidant and gain entry into the fast-growing $10.3 billion cardiac-rhythm management market. Boston Scientific’s enthusiasm for the merger was not dampened by Guidant’s 1-23-06 announcement that it was enlarging its previous recall of nine of its pacemaker models.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.